Skip to main content

COVID-19

academics

 

Clinical research courses

  • Moderna sends COVID-19 booster shot for NIH testing

    Moderna, Inc a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announces that it has completed manufacturing of clinical trial material for its variant-specific vaccine candidate, mRNA-1273.351, against the SARS-CoV-2 variant known as B.1.351 first identified in the Republic of South Africa, and has shipped doses to the National Institutes of Health (NIH) for a Phase 1 clinical trial that will be led and funded by the NIH’s National Institute of Allergy and Infectious Diseases (NIAID).

  • New potential drug to treat SARS-CoV-2

    A federally approved heart medication shows significant effectiveness in interfering with SARS-CoV-2 entry into the human cell host, according to a new study by a research team from Texas A&M University and The University of Texas Medical Branch (UTMB).

    The medication bepridil, which goes by the trade name Vascor, is currently approved by the U.S. Food and Drug Administration (FDA) to treat angina, a heart condition.

  • WHO COVID-19 Investigation Is Tainted by Conflict of Interest

    AIDS Healthcare Foundation (AHF) calls for the team that is currently investigating the origins of the novel coronavirus in Wuhan, China to be disbanded and reassembled by a completely independent panel with unfettered access and diplomatic immunity for all members. A conflict of interest of one of the current WHO-sanctioned team members and the tightly choreographed format of the field research cast doubt on the investigation’s credibility and the validity of the eventual findings.

  • Smiths Detection's BioFlash shown to detect airborne COVID-19

    Smiths Detection, a global leader in threat detection and security screening technologies, reports that its BioFlash® Biological Identifier is capable of detecting SARS-CoV-2 in the air following tests conducted by the United States Army Medical Research Institute of Infectious Diseases (USAMRIID).

  • Daiichi Sankyo to manufacture AstraZeneca COVID-19 vaccine in Japan

    Daiichi Sankyo Company, Limited is pleased to announce that it recently entered into an outsourcing agreement with AstraZeneca K.K. (hereinafter, AstraZeneca) to manufacture the AstraZeneca-developed COVID-19 vaccine, AZD1222, in Japan.

  • A machine-learning approach to finding treatment options for Covid-19

    When the Covid-19 pandemic struck in early 2020, doctors and researchers rushed to find effective treatments. There was little time to spare. "Making new drugs takes forever," says Caroline Uhler, a computational biologist in MIT's Department of Electrical Engineering and Computer Science and the Institute for Data, Systems and Society, and an associate member of the Broad Institute of MIT and Harvard. "Really, the only expedient option is to repurpose existing drugs."

  • COVID WHO Investigation: A Smoke Screen for China

    Amid premature and incomplete reports from the World Health Organization’s (WHO) investigative team which has just concluded its work in China to discover the origins of SARS-CoV-2, AIDS Healthcare Foundation (AHF) calls for the investigation to continue and for the team to release a detailed report and hold a legitimate press conference after leaving China.

  • Phase 3 trial recruitment starts for COVID-19 vaccine of Janssen

    The University of Kentucky has been selected as a testing site for the Janssen Pharmaceutical Companies of Johnson & Johnson’s Phase 3 clinical research study ENSEMBLE 2, which is evaluating the safety and efficacy of a two-dose regimen of Janssen’s COVID-19 vaccine candidate.

  • India is also providing vaccines to neighboring countries

    In this difficult time when the whole world has suffered from an unknown, invisible and unknowable virus COVID-19, India is ready to provide its cut to the world community. India, which has become the Corona vaccine, is running the world's largest vaccination campaign today. Not only this, along with the vaccination of Corona to Indians, India is also providing vaccines to many other countries.

  • 21% of India’s adult population had COVID-19 by mid-December : Serological Survey

    According to the third national serological-survey report of the Indian Council of Medical Research (ICMR), over 21 percent of the population, aged 18 years and above, showed evidence of past exposure to COVID-19. The data on seroprevalenceamong those aged 10-17 was found to be 25.3 percent.

Subscribe to COVID-19